View organization page for Bristol Myers Squibb

1,749,283 followers

As part of our vision to transform patients’ lives through science, we are committed to addressing the needs of people living with neurological and neuropsychiatric conditions – pursuing bold science while always keeping patients at the center. Hear from Dr. Ken Kramer, PhD as our team prepares to attend the upcoming NEI Fall Congress, and learn more about our work in neuroscience: https://bit.ly/3X6bO6O #OneBMS

Carra Simpson, Ph.D

Medical Learning Lead Neuropsychiatry @ BMS | PhD Microbiome-Gut Brain Axis

3d

That’s a booth I’d stop by! #OneBMS

Tania Small, MD

SVP & Head of Global Medical Affairs | Powering Patient-Driven Science, Bold Innovation & Equitable Access | Board member

2d

Excited to see you there!! Thanks Ken!

Andrea C. W.

Senior Medical Director, Psychiatry

3d

Good to see you, Ken!

Like
Reply

Translating complexity into meaningful care remains the core challenge in neuropsychiatric drug development. BMS’s emphasis on patient-centered neuroscience is notable, not just identifying targets, but shaping interventions to account for real-world variability in cognition, mood, and function. Looking forward to seeing how this approach is evolving across programs and platforms.

Like
Reply
See more comments

To view or add a comment, sign in

Explore content categories